Etanercept biosimilar - LG Life Sciences

Drug Profile

Etanercept biosimilar - LG Life Sciences

Alternative Names: LBEC-0101; TNFcept

Latest Information Update: 29 Mar 2016

Price : $50

At a glance

  • Originator LG Life Sciences
  • Developer LG Life Sciences; Mochida Pharmaceutical
  • Class Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Rheumatoid arthritis

Most Recent Events

  • 17 Mar 2016 LG Life Sciences plans an extension phase III trial for Rheumatoid arthritis (Adjunctive treatment) in South Korea (SC) (NCT02715908)
  • 15 Mar 2016 Biomarkers information updated
  • 10 Feb 2015 LG Life Sciences and Mochida Pharmaceutical plan a phase III trial for Rheumatoid arthritis in South Korea and Japan (NCT02357069)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top